Business Wire

dataplor Raises $20.5M Series B to Scale Global Location Intelligence and Accelerate Product Growth

3.6.2025 16:00:00 CEST | Business Wire | Press Release

Share

dataplor, a leading provider of global location intelligence, today announced the close of a $20.5 million Series B funding round, led by F-Prime, with participation from Spark Capital, FFVC, Acronym Venture Capital, Two Lanterns Venture Capital, APA Ventures, dara5, and Alumni Ventures.

The new investment will accelerate dataplor’s growth, expand its product offerings, and scale its global location intelligence products. This funding comes on the heels of dataplor’s global mobility product launch, which delivers monthly refreshed, privacy-compliant foot traffic data across international markets—unlocking powerful new insights for customers. Combined with its proprietary Point of Interest (POI) data, dataplor now offers businesses the most comprehensive and privacy-forward view of real-world consumer behavior on a global scale.

“Businesses around the world are realizing how critical accurate, dynamic location data is to their strategy,” said Gaurav Tuli, Partner at F-Prime. “dataplor has built a truly differentiated solution that combines global scale, data quality, and compliance in a way we haven’t seen before. We’re thrilled to support their next phase of growth.”

Businesses rely on precise, dynamic location data to make strategic decisions—yet much of the available international POI data is outdated, incomplete, or inaccurate, particularly in emerging markets. This gap creates billions of dollars in missed opportunities for companies trying to expand, allocate resources, or understand consumer behavior across borders. dataplor’s location intelligence fills this void, covering over 350 million POIs in more than 250 countries and territories, serving customers in technology, financial services, retail, logistics, consumer packaged goods (CPG), mapping, real estate, and more. Today, dataplor supports dozens of enterprise customers globally, including multiple Fortune 100 companies, embedding its data into critical workflows across geospatial, operations, and growth teams.

Its data powers high-impact decisions for global brands—from helping EV networks predict charger demand in real time to enabling insurers to model property risk with unmatched geospatial precision to empowering CPG leaders to identify distributors and grow in under-mapped regions. By combining AI, machine learning, and human validation, dataplor ensures its datasets remain accurate, comprehensive, and current—even in historically under-mapped regions.

With a privacy-first approach, dataplor ensures no personally identifiable information (PII) is ever used. This provides enterprise clients with full confidence in regulatory compliance and ethical data practices.

“Our customers demand accurate, fresh, and globally compliant location data,” said Geoff Michener, Founder and CEO of dataplor. “With this new funding, we’re doubling down on our commitment to deliver the highest quality insights, while expanding our geographic coverage, enriching our product suite, and driving real business impact through seamless customer integration.”

About dataplor

dataplor is a leading provider of point-of-interest (POI) and mobility data that helps global enterprises grow abroad by mapping tough-to-reach markets with a privacy-first approach. As the majority of international location data is often inaccurate and quickly outdated, dataplor goes several steps beyond the industry standard, helping the world’s largest companies across technology, mapping, search, third-party logistics, consumer packaged goods (CPG), telecom, investing, real estate, and finance understand location intelligence about any commercial or physical location in real-time, fueling their expansion abroad.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603685452/en/

Contacts

media@dataplor.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye